Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy
Abstract In recent years, cancer immunotherapy has emerged as an exciting cancer treatment. Immune checkpoint blockade brings new opportunities for more researchers and clinicians. Programmed cell death receptor-1 (PD-1) is a widely studied immune checkpoint, and PD-1 blockade therapy has shown prom...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-023-01966-4 |
| _version_ | 1827905251781378048 |
|---|---|
| author | Songlin Liu Haiyang Wang Xinzhe Shao Haonan Chen Shushu Chao Yanyan Zhang Zhaoju Gao Qingqiang Yao Pingping Zhang |
| author_facet | Songlin Liu Haiyang Wang Xinzhe Shao Haonan Chen Shushu Chao Yanyan Zhang Zhaoju Gao Qingqiang Yao Pingping Zhang |
| author_sort | Songlin Liu |
| collection | DOAJ |
| description | Abstract In recent years, cancer immunotherapy has emerged as an exciting cancer treatment. Immune checkpoint blockade brings new opportunities for more researchers and clinicians. Programmed cell death receptor-1 (PD-1) is a widely studied immune checkpoint, and PD-1 blockade therapy has shown promising results in a variety of tumors, including melanoma, non-small cell lung cancer and renal cell carcinoma, which greatly improves patient overall survival and becomes a promising tool for the eradication of metastatic or inoperable tumors. However, low responsiveness and immune-related adverse effects currently limit its clinical application. Overcoming these difficulties is a major challenge to improve PD-1 blockade therapies. Nanomaterials have unique properties that enable targeted drug delivery, combination therapy through multidrug co-delivery strategies, and controlled drug release through sensitive bonds construction. In recent years, combining nanomaterials with PD-1 blockade therapy to construct novel single-drug-based or combination therapy-based nano-delivery systems has become an effective mean to address the limitations of PD-1 blockade therapy. In this study, the application of nanomaterial carriers in individual delivery of PD-1 inhibitors, combined delivery of PD-1 inhibitors and other immunomodulators, chemotherapeutic drugs, photothermal reagents were reviewed, which provides effective references for designing new PD-1 blockade therapeutic strategies. Graphical Abstract |
| first_indexed | 2024-03-13T00:39:20Z |
| format | Article |
| id | doaj.art-0be0a5d6e8f94533a3d3b7fb608e0db0 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-03-13T00:39:20Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-0be0a5d6e8f94533a3d3b7fb608e0db02023-07-09T11:23:40ZengBMCJournal of Nanobiotechnology1477-31552023-07-0121112410.1186/s12951-023-01966-4Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapySonglin Liu0Haiyang Wang1Xinzhe Shao2Haonan Chen3Shushu Chao4Yanyan Zhang5Zhaoju Gao6Qingqiang Yao7Pingping Zhang8School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceSchool of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong ProvinceAbstract In recent years, cancer immunotherapy has emerged as an exciting cancer treatment. Immune checkpoint blockade brings new opportunities for more researchers and clinicians. Programmed cell death receptor-1 (PD-1) is a widely studied immune checkpoint, and PD-1 blockade therapy has shown promising results in a variety of tumors, including melanoma, non-small cell lung cancer and renal cell carcinoma, which greatly improves patient overall survival and becomes a promising tool for the eradication of metastatic or inoperable tumors. However, low responsiveness and immune-related adverse effects currently limit its clinical application. Overcoming these difficulties is a major challenge to improve PD-1 blockade therapies. Nanomaterials have unique properties that enable targeted drug delivery, combination therapy through multidrug co-delivery strategies, and controlled drug release through sensitive bonds construction. In recent years, combining nanomaterials with PD-1 blockade therapy to construct novel single-drug-based or combination therapy-based nano-delivery systems has become an effective mean to address the limitations of PD-1 blockade therapy. In this study, the application of nanomaterial carriers in individual delivery of PD-1 inhibitors, combined delivery of PD-1 inhibitors and other immunomodulators, chemotherapeutic drugs, photothermal reagents were reviewed, which provides effective references for designing new PD-1 blockade therapeutic strategies. Graphical Abstracthttps://doi.org/10.1186/s12951-023-01966-4PD-1 immune checkpointsPD-1 blockade therapyNano-delivery systemsCombination therapyTumor |
| spellingShingle | Songlin Liu Haiyang Wang Xinzhe Shao Haonan Chen Shushu Chao Yanyan Zhang Zhaoju Gao Qingqiang Yao Pingping Zhang Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy Journal of Nanobiotechnology PD-1 immune checkpoints PD-1 blockade therapy Nano-delivery systems Combination therapy Tumor |
| title | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy |
| title_full | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy |
| title_fullStr | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy |
| title_full_unstemmed | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy |
| title_short | Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy |
| title_sort | advances in pd 1 signaling inhibition based nano delivery systems for tumor therapy |
| topic | PD-1 immune checkpoints PD-1 blockade therapy Nano-delivery systems Combination therapy Tumor |
| url | https://doi.org/10.1186/s12951-023-01966-4 |
| work_keys_str_mv | AT songlinliu advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT haiyangwang advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT xinzheshao advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT haonanchen advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT shushuchao advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT yanyanzhang advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT zhaojugao advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT qingqiangyao advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy AT pingpingzhang advancesinpd1signalinginhibitionbasednanodeliverysystemsfortumortherapy |